Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

RPR/INGN-201 + radiotherapy provides supraadditive effects in prostate cancer xenograft models

Nov. 17, 1999

Lorus files IND seeking clearance for phase I/II clinical trials of GTI-2040

Nov. 17, 1999

Foscan receives orphan drug designation in U.S.; MAA accepted in E.U.

Nov. 17, 1999

Pharmaceutical agents useful as vitronectin antagonists and methods of use

Nov. 17, 1999

Kinase inhibitors developed at Boehringer Ingelheim as potential anticancer agents

Nov. 17, 1999

Ontogen completes phase I multidose oral study of MDR compound

Nov. 17, 1999

Preclinical data highlight Xcytrin's anticancer activity and novel mechanism of action

Nov. 17, 1999

New data reported on thalidomide for several cancer indications

Nov. 17, 1999

OHSU study will evaluate vitamin D in patients with recurring prostate cancer

Nov. 16, 1999

Kotobuki presents new sulfonamide MMP inhibitors

Nov. 15, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...